EP3883351
Active European LitigationCommercial IPPCSK9 antibodies for cholesterol reduction
Assignee / Proprietor: Sanofi-Aventis
Unitary Status
Unitary Patent (UP)
Classification
Standard Patent
Technology Domain
Biopharmaceutical Formulation / Biologics
Estimated Expiry Horizon
c. 2033
Commercial Exposure & Market Stakes
Asset linked to high-value commercial operations: PCSK9 Monoclonal Antibody (Alirocumab / Evolocumab - €1.8B Global Sales). Litigation orders across European jurisdictions directly threaten supply chains, customs clearance, and distribution channels.
Active Court Dockets Involving Patent EP3883351
1 proceeding(s) recordedActive Proceeding
Claimant on Record v. Defendant on Record
Representing Counsel: Counsel on Record vs Counsel on RecordView Complete Case Dossier & Teardown →
Tracking patent EP3883351 across Europe?
Get an immediate email alert whenever an opt-out, revocation counterclaim, or preliminary injunction application is lodged against this patent in any European jurisdiction.